Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
A phase 3 trial of 5-Aminolevulinic acid in ovarian cancer, run by NX Development Corp, now recruiting.
Overview
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) is a phase 3 interventional study registered as NCT05804370 by NX Development Corp, with 170 participants planned, started 2024-05-30 and due to reach its primary completion in 2028-09. Interventions recorded: Gleolan. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase 3 Multicenter Study of Gleolan® (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Suspected Newly Diagnosed or Recurrent Epithelial Ovarian Cancer
Phase
Phase 3
Sponsor
NX Development Corp
Registry
Enrolled
170